Fulcrum Therapeutics and Slate Medicines Merge for Migraine Therapies

M&A · Partnership
โดย ExecEdge·US·Read original
Summary · why it matters

Fulcrum Therapeutics and Slate Medicines are merging to advance next-generation migraine and headache disorder treatments, with the combined company operating as Slate Medicines and trading on Nasdaq under the ticker SLTE. Slate secured an oversubscribed concurrent private placement of $245 million from healthcare investors led by Frazier Life Sciences, with participation from Forbion, RA Capital Management, and Deep Track Capital. The new company's cash balance is expected to fund operations into 2029. Slate Medicines CEO Gregory Oakes said the merger and financing will provide resources to advance SLTE-1009 and the rest of the pipeline through potentially meaningful clinical milestones.

Impact on stocks 5

Biotech & Genomic Medicine▲ · 5 stocks

Off-coverage companies 5

Slate MedicinesPrivate▲ Positive
Capitalrelevance

Slate Medicines secures $245M private placement and merger to advance migraine pipeline, funding operations into 2029.

Deep Track CapitalPrivate± Mixed
relevance

ForbionPrivate± Mixed
relevance

Frazier Life SciencesPrivate± Mixed
relevance

RA Capital ManagementPrivate± Mixed
relevance

© 2026 MarketDXNews